ARUP's Laboratory Test Directory

HNPCC/Lynch Syndrome (PMS2) Sequencing and Deletion/Duplication : 0051737
[ image for: Patient History for HNPCC/Lynch Syndrome Testing]
Patient History for HNPCC/Lynch Syndrome Testing
  


Mnemonic: PMS2 FGA

Methodology: Polymerase Chain Reaction/Sequencing/Multiplex Ligation-dependent Probe Amplification
Performed: Varies
Reported: Within 35 days
Specimen Required: Collect: Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or B).

Specimen Preparation: Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature: Refrigerated.

Stability (collection to initiation of testing): Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable

Interpretive Data: Background information for HNPCC/Lynch Syndrome (PMS2) Sequencing and Deletion/Duplication
Characteristics of Lynch Syndrome:
Increased risk of colorectal and extra-colonic cancers including endometrial, renal pelvis, ureter, ovary, stomach, small intestine and hepatobiliary tract.
Incidence:
1-2 percent of colorectal cancer is due to mismatch repair gene mutations.
Inheritance:
Autosomal dominant.
Penetrance:
Unknown for PMS2 mutations.
Cause:
Pathogenic germline MLH1, MSH2, MSH6, and PMS2 gene mutations.
Gene tested:
PMS2
Clinical Sensitivity:
Less than 5 percent of Lynch syndrome cases are due to PMS2 mutations.
Methodology:
Bidirectional sequencing of PMS2 coding regions and intron-exon boundaries; multiplex ligation-dependent probe amplification (MLPA) to detect large PMS2 exonic deletions.
Analytical Sensitivity & Specificity:
99 percent.
Limitations:
Rare diagnostic errors can occur due to primer and probe site mutations. Regulatory region mutations and deep intronic mutations will not be detected. Mutations in genes other than PMS2 are not evaluated.

This test is performed pursuant to an agreement with Roche Molecular Systems, Inc.



Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.

Refer to Statement C under Testing Information at http://www.aruplab.com.
Note: Suspected deletions or duplications in exons 12-15 require additional sequencing to exclude pseudogene copy number variants.  Additional charges apply.
CPT Code(s): Sequencing: 83891 Isolation; 83898 x18 Amplification; 83904 x15 Sequencing; 83909 Capillary electrophoresis.
Del/Dup:
83896 x15 Nucleic Acid Probes; 83898 x15 Amplification; 83914 x15 Extension; 83909 Capillary electrophoresis; 83912 Interpretation and report. If pseudogene analysis is performed, add: 83898 x6 Amplification; 83904 x5 Sequencing; 83909 Capillary electrophoresis. - Additional CPT code modifiers may be required for procedures performed to test for oncologic or inherited disorders.
Cross References: Lynch Syndrome (HNPCC/Lynch Syndrome (PMS2) Sequencing and Deletion/Duplication) , PMS2 (HNPCC/Lynch Syndrome (PMS2) Sequencing and Deletion/Duplication)
 
 

 

 

 
All ARUP Sites:        www.aruplab.com     ·     www.arupconsult.com     ·     www.arup.utah.edu     ·     www.childx.org     ·     www.utahblood.org